DIA, in collaboration with FDA, is organizing a biosimilars conference in Washington DC, on September 12-13, 2012.
The Biologics Price Competition and Innovation Act (BPCI Act) of 2009 was enacted as part of the Affordable Care Act. This conference will deal with the scientific and regulatory issues related to the demonstration of biosimilarity, focusing both on the FDA’s current thinking on approaches to biosimilar development as well as perspectives of other regulators. In the conference, the FDA guidance will be discussed from the perspectives of regulators and industry.
If you would like to attend the conference, you can get more information from here.